nuclear receptor subfamily 1 group D member 1Genealiases: EAR1 · REVERBA · REVERBalpha · THRA1 · THRAL · ear-1
Q-omics provides the consensus-scored NR1D1 profile across patient tissues and cancer cell-line models. NR1D1 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in COAD. Among the 18 cancer types available for tumor–normal comparison, NR1D1 is differentially expressed in 15, with the highest sampling consensus in THCA. Additionally, NR1D1 RNA expression shows 16,494 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight COAD, THCA, and ACC as cancer lineages where NR1D1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NR1D1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NR1D1 survival associations across molecular data types. NR1D1 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (4) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NR1D1 RNA expression–survival associations across cancer types. High NR1D1 expression shows unfavorable associations in COAD, STAD, ACC, LUAD and GBM, but favorable associations in UCEC. The COAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify COAD as the clearest survival context for NR1D1 RNA expression.
This table summarizes NR1D1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 3. The strongest signals are observed in THCA for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for NR1D1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NR1D1 shows lower tumor expression in UCEC and higher tumor expression in THCA, COAD, KIRC, HNSC and KIRP. The THCA box plot shows higher NR1D1 RNA expression in tumor versus normal tissue (log2 FC = +2.677, t-test p < 0.001).
This table shows molecular features associated with NR1D1 in patient tissues and cancer cell lines. In patient samples, NR1D1 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, NR1D1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and SOFT_TISSUE.
